A study of an oral drug for anemia from chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an oral medication (AND017) to see if it can safely help raise hemoglobin levels in people with anemia caused by chemotherapy. If you have cancer (not leukemia) and are currently on chemo, this trial might help manage your anemia and improve your energy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that does not start in your blood or bone marrow (not leukemia).
- You must have already received at least one cycle of chemotherapy or similar cancer treatment that is expected to lower your blood counts, and you plan to continue it for at least 8 weeks.
- Your ability to do daily activities should be mostly good (score 0 to 2 on the ECOG scale).
- Your blood tests should show anemia (hemoglobin less than 10 g/dL) on two tests taken at least one week apart.
- Your kidney and liver function should be within acceptable ranges, and you must have enough iron, folate, and vitamin B12 in your body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, SSS06, to help people whose red blood cell count drops too low after chemotherapy. It aims to reduce fatigue and other symptoms of anemia, making it easier to continue cancer treatment.
This trial tests a new pill, AND017, for people with cancer who have low red blood cell counts (anemia) and are not getting chemotherapy. The goal is to see if the drug helps raise hemoglobin levels and reduce fatigue.
This study tests a new medication (SAL-0951) for treating low red blood cell counts (anemia) caused by chemotherapy in people with certain types of cancer that are not curable. It may help improve energy and reduce the need for blood transfusions.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
Hear when a new Chemotherapy Induced Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.